Upcoming

2023

Kidney/renal Cancer Drugs Market

Kidney/Renal Cancer Drugs Market

by Therapy Type (Targeted Therapy, Chemotherapy, Immunotherapy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals	Report Code: A01179	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Kidney/renal Cancer Drugs Market

Request Now !

Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.

The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.

Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.

The market is expected to register substantial growth in the near future. This can be attributed to the various strategies adopted by the leading industry players. One of the key strategies adopted is collaboration agreement. Recently, Roche signed an agreement with Celldex Therapeutics, Inc. in order to evaluate the safety and efficacy of its immunotherapy drug, namely, MPDL3280A in combination with latters CD27 targeting investigational antibody, varlilumab for the treatment of renal cell carcinoma.

To provide a detailed market assessment, the report segments the kidney cancer drugs market on the basis of therapy type and geography. On the basis of therapy type, the market is segmented into Targeted Therapy, Chemotherapy and Immunotherapy. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Novartis AG and others, are also provided in the report.

KEY MARKET BENEFITS:

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global kidney cancer drugs market
Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used targeted therapy drugs, evolving role of immunotherapies and in-line extensions opted for existing drugs
The report covers the detailed quantitative analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
The studies evaluating competitive landscape and value chain has been taken into account in this report to help in understanding the competitive environment across the geographies
A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
Owing to an emerging pipeline in the kidney cancer drugs market, clinical studies have also been taken into account to better understand the market potential and opportunities
The kidney cancer drugs market scenario is comprehensively analyzed in accordance with the key regions
Competitive intelligence highlights the business practises followed by leading market players across geographies

Kidney/Renal Cancer Drugs Market Report Highlights

Aspects	Details
By Therapy Type	Targeted Therapy Approved drugs Pipeline drugs Chemotherapy Immunotherapy
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, UK, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, UAE, Rest of LAMEA)
Key Market Players	F. Hoffmann-La Roche AG, Onyx Pharmaceuticals Inc., Bayer AG, Genentech, Inc., Pfizer, Inc., Novartis AG, Cipla Limited, Amgen, GlaxoSmithKline plc, Active Biotech AB

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: KIDNEY/RENAL CANCER DRUGS MARKET, BY THERAPY TYPE
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Therapy Type
- 4.2. Targeted Therapy
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
  - 4.2.4. Approved drugs
    - 4.2.4.1. Market Size and Forecast
  - 4.2.4. Pipeline drugs
    - 4.2.4.1. Market Size and Forecast
- 4.3. Chemotherapy
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
- 4.4. Immunotherapy
  - 4.4.1. Key Market Trends, Growth Factors and Opportunities
  - 4.4.2. Market Size and Forecast, By Region
  - 4.4.3. Market Share Analysis, By Country
CHAPTER 5: KIDNEY/RENAL CANCER DRUGS MARKET, BY REGION
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Region
- 5.2. North America
  - 5.2.1. Key Market Trends and Opportunities
  - 5.2.2. Market Size and Forecast, By Therapy Type
  - 5.2.3. Market Size and Forecast, By Country
  - 5.2.4. U.S. Kidney/renal Cancer Drugs Market
    - 5.2.4.1. Market Size and Forecast, By Therapy Type
  - 5.2.5. Canada Kidney/renal Cancer Drugs Market
    - 5.2.5.1. Market Size and Forecast, By Therapy Type
  - 5.2.6. Mexico Kidney/renal Cancer Drugs Market
    - 5.2.6.1. Market Size and Forecast, By Therapy Type
- 5.3. Europe
  - 5.3.1. Key Market Trends and Opportunities
  - 5.3.2. Market Size and Forecast, By Therapy Type
  - 5.3.3. Market Size and Forecast, By Country
  - 5.3.4. France Kidney/renal Cancer Drugs Market
    - 5.3.4.1. Market Size and Forecast, By Therapy Type
  - 5.3.5. Germany Kidney/renal Cancer Drugs Market
    - 5.3.5.1. Market Size and Forecast, By Therapy Type
  - 5.3.6. Italy Kidney/renal Cancer Drugs Market
    - 5.3.6.1. Market Size and Forecast, By Therapy Type
  - 5.3.7. Spain Kidney/renal Cancer Drugs Market
    - 5.3.7.1. Market Size and Forecast, By Therapy Type
  - 5.3.8. UK Kidney/renal Cancer Drugs Market
    - 5.3.8.1. Market Size and Forecast, By Therapy Type
  - 5.3.9. Russia Kidney/renal Cancer Drugs Market
    - 5.3.9.1. Market Size and Forecast, By Therapy Type
  - 5.3.10. Rest Of Europe Kidney/renal Cancer Drugs Market
    - 5.3.10.1. Market Size and Forecast, By Therapy Type
- 5.4. Asia-Pacific
  - 5.4.1. Key Market Trends and Opportunities
  - 5.4.2. Market Size and Forecast, By Therapy Type
  - 5.4.3. Market Size and Forecast, By Country
  - 5.4.4. China Kidney/renal Cancer Drugs Market
    - 5.4.4.1. Market Size and Forecast, By Therapy Type
  - 5.4.5. Japan Kidney/renal Cancer Drugs Market
    - 5.4.5.1. Market Size and Forecast, By Therapy Type
  - 5.4.6. India Kidney/renal Cancer Drugs Market
    - 5.4.6.1. Market Size and Forecast, By Therapy Type
  - 5.4.7. South Korea Kidney/renal Cancer Drugs Market
    - 5.4.7.1. Market Size and Forecast, By Therapy Type
  - 5.4.8. Australia Kidney/renal Cancer Drugs Market
    - 5.4.8.1. Market Size and Forecast, By Therapy Type
  - 5.4.9. Thailand Kidney/renal Cancer Drugs Market
    - 5.4.9.1. Market Size and Forecast, By Therapy Type
  - 5.4.10. Malaysia Kidney/renal Cancer Drugs Market
    - 5.4.10.1. Market Size and Forecast, By Therapy Type
  - 5.4.11. Indonesia Kidney/renal Cancer Drugs Market
    - 5.4.11.1. Market Size and Forecast, By Therapy Type
  - 5.4.12. Rest of Asia Pacific Kidney/renal Cancer Drugs Market
    - 5.4.12.1. Market Size and Forecast, By Therapy Type
- 5.5. LAMEA
  - 5.5.1. Key Market Trends and Opportunities
  - 5.5.2. Market Size and Forecast, By Therapy Type
  - 5.5.3. Market Size and Forecast, By Country
  - 5.5.4. Brazil Kidney/renal Cancer Drugs Market
    - 5.5.4.1. Market Size and Forecast, By Therapy Type
  - 5.5.5. South Africa Kidney/renal Cancer Drugs Market
    - 5.5.5.1. Market Size and Forecast, By Therapy Type
  - 5.5.6. Saudi Arabia Kidney/renal Cancer Drugs Market
    - 5.5.6.1. Market Size and Forecast, By Therapy Type
  - 5.5.7. UAE Kidney/renal Cancer Drugs Market
    - 5.5.7.1. Market Size and Forecast, By Therapy Type
  - 5.5.8. Argentina Kidney/renal Cancer Drugs Market
    - 5.5.8.1. Market Size and Forecast, By Therapy Type
  - 5.5.9. Rest of LAMEA Kidney/renal Cancer Drugs Market
    - 5.5.9.1. Market Size and Forecast, By Therapy Type
CHAPTER 6: COMPETITIVE LANDSCAPE
- 6.1. Introduction
- 6.2. Top Winning Strategies
- 6.3. Product Mapping Of Top 10 Player
- 6.4. Competitive Dashboard
- 6.5. Competitive Heatmap
- 6.6. Top Player Positioning,2022
CHAPTER 7: COMPANY PROFILES
- 7.1. Active Biotech AB
  - 7.1.1. Company Overview
  - 7.1.2. Key Executives
  - 7.1.3. Company Snapshot
  - 7.1.4. Operating Business Segments
  - 7.1.5. Product Portfolio
  - 7.1.6. Business Performance
  - 7.1.7. Key Strategic Moves and Developments
- 7.2. Amgen
  - 7.2.1. Company Overview
  - 7.2.2. Key Executives
  - 7.2.3. Company Snapshot
  - 7.2.4. Operating Business Segments
  - 7.2.5. Product Portfolio
  - 7.2.6. Business Performance
  - 7.2.7. Key Strategic Moves and Developments
- 7.3. Bayer AG
  - 7.3.1. Company Overview
  - 7.3.2. Key Executives
  - 7.3.3. Company Snapshot
  - 7.3.4. Operating Business Segments
  - 7.3.5. Product Portfolio
  - 7.3.6. Business Performance
  - 7.3.7. Key Strategic Moves and Developments
- 7.4. Cipla Limited
  - 7.4.1. Company Overview
  - 7.4.2. Key Executives
  - 7.4.3. Company Snapshot
  - 7.4.4. Operating Business Segments
  - 7.4.5. Product Portfolio
  - 7.4.6. Business Performance
  - 7.4.7. Key Strategic Moves and Developments
- 7.5. F. Hoffmann-La Roche AG
  - 7.5.1. Company Overview
  - 7.5.2. Key Executives
  - 7.5.3. Company Snapshot
  - 7.5.4. Operating Business Segments
  - 7.5.5. Product Portfolio
  - 7.5.6. Business Performance
  - 7.5.7. Key Strategic Moves and Developments
- 7.6. Genentech, Inc.
  - 7.6.1. Company Overview
  - 7.6.2. Key Executives
  - 7.6.3. Company Snapshot
  - 7.6.4. Operating Business Segments
  - 7.6.5. Product Portfolio
  - 7.6.6. Business Performance
  - 7.6.7. Key Strategic Moves and Developments
- 7.7. GlaxoSmithKline Plc
  - 7.7.1. Company Overview
  - 7.7.2. Key Executives
  - 7.7.3. Company Snapshot
  - 7.7.4. Operating Business Segments
  - 7.7.5. Product Portfolio
  - 7.7.6. Business Performance
  - 7.7.7. Key Strategic Moves and Developments
- 7.8. Novartis AG
  - 7.8.1. Company Overview
  - 7.8.2. Key Executives
  - 7.8.3. Company Snapshot
  - 7.8.4. Operating Business Segments
  - 7.8.5. Product Portfolio
  - 7.8.6. Business Performance
  - 7.8.7. Key Strategic Moves and Developments
- 7.9. Onyx Pharmaceuticals Inc.
  - 7.9.1. Company Overview
  - 7.9.2. Key Executives
  - 7.9.3. Company Snapshot
  - 7.9.4. Operating Business Segments
  - 7.9.5. Product Portfolio
  - 7.9.6. Business Performance
  - 7.9.7. Key Strategic Moves and Developments
- 7.10. Pfizer, Inc.
  - 7.10.1. Company Overview
  - 7.10.2. Key Executives
  - 7.10.3. Company Snapshot
  - 7.10.4. Operating Business Segments
  - 7.10.5. Product Portfolio
  - 7.10.6. Business Performance
  - 7.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 2. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 5. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 6. NORTH AMERICA KIDNEY/RENAL CANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 7. NORTH AMERICA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 8. U.S. KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 9. CANADA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 10. MEXICO KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 11. EUROPE KIDNEY/RENAL CANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. EUROPE KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 13. FRANCE KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 14. GERMANY KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 15. ITALY KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 16. SPAIN KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 17. UK KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 18. RUSSIA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 19. REST OF EUROPE KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 20. ASIA-PACIFIC KIDNEY/RENAL CANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. ASIA-PACIFIC KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 22. CHINA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 23. JAPAN KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 24. INDIA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 25. SOUTH KOREA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 26. AUSTRALIA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 27. THAILAND KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 28. MALAYSIA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 29. INDONESIA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 30. REST OF ASIA PACIFIC KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 31. LAMEA KIDNEY/RENAL CANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 32. LAMEA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 33. BRAZIL KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 34. SOUTH AFRICA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 35. SAUDI ARABIA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 36. UAE KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 37. ARGENTINA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 38. REST OF LAMEA KIDNEY/RENAL CANCER DRUGS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 39. ACTIVE BIOTECH AB: KEY EXECUTIVES
TABLE 40. ACTIVE BIOTECH AB: COMPANY SNAPSHOT
TABLE 41. ACTIVE BIOTECH AB: OPERATING SEGMENTS
TABLE 42. ACTIVE BIOTECH AB: PRODUCT PORTFOLIO
TABLE 43. ACTIVE BIOTECH AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. AMGEN: KEY EXECUTIVES
TABLE 45. AMGEN: COMPANY SNAPSHOT
TABLE 46. AMGEN: OPERATING SEGMENTS
TABLE 47. AMGEN: PRODUCT PORTFOLIO
TABLE 48. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. BAYER AG: KEY EXECUTIVES
TABLE 50. BAYER AG: COMPANY SNAPSHOT
TABLE 51. BAYER AG: OPERATING SEGMENTS
TABLE 52. BAYER AG: PRODUCT PORTFOLIO
TABLE 53. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 54. CIPLA LIMITED: KEY EXECUTIVES
TABLE 55. CIPLA LIMITED: COMPANY SNAPSHOT
TABLE 56. CIPLA LIMITED: OPERATING SEGMENTS
TABLE 57. CIPLA LIMITED: PRODUCT PORTFOLIO
TABLE 58. CIPLA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 59. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 60. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 61. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 62. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 63. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64. GENENTECH, INC.: KEY EXECUTIVES
TABLE 65. GENENTECH, INC.: COMPANY SNAPSHOT
TABLE 66. GENENTECH, INC.: OPERATING SEGMENTS
TABLE 67. GENENTECH, INC.: PRODUCT PORTFOLIO
TABLE 68. GENENTECH, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 70. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 71. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 72. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 73. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. NOVARTIS AG: KEY EXECUTIVES
TABLE 75. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 76. NOVARTIS AG: OPERATING SEGMENTS
TABLE 77. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 78. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. ONYX PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 80. ONYX PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 81. ONYX PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 82. ONYX PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 83. ONYX PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. PFIZER, INC.: KEY EXECUTIVES
TABLE 85. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 86. PFIZER, INC.: OPERATING SEGMENTS
TABLE 87. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 88. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET SEGMENTATION
FIGURE 2. GLOBAL KIDNEY/RENAL CANCER DRUGS MARKET
FIGURE 3. SEGMENTATION KIDNEY/RENAL CANCER DRUGS MARKET
FIGURE 4. TOP INVESTMENT POCKET IN KIDNEY/RENAL CANCER DRUGS MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALKIDNEY/RENAL CANCER DRUGS MARKET
FIGURE 11. KIDNEY/RENAL CANCER DRUGS MARKET SEGMENTATION, BY BY THERAPY TYPE
FIGURE 12. KIDNEY/RENAL CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. KIDNEY/RENAL CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. KIDNEY/RENAL CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 15. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 16. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 17. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 18. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 19. COMPETITIVE DASHBOARD
FIGURE 20. COMPETITIVE HEATMAP: KIDNEY/RENAL CANCER DRUGS MARKET
FIGURE 21. Top player positioning, 2022
FIGURE 22. ACTIVE BIOTECH AB: NET SALES, 2020-2022 ($MILLION)
FIGURE 23. ACTIVE BIOTECH AB: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 24. ACTIVE BIOTECH AB: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 25. AMGEN: NET SALES, 2020-2022 ($MILLION)
FIGURE 26. AMGEN: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 27. AMGEN: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 28. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 29. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 30. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 31. CIPLA LIMITED: NET SALES, 2020-2022 ($MILLION)
FIGURE 32. CIPLA LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 33. CIPLA LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 34. F. HOFFMANN-LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 35. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 36. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 37. GENENTECH, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 38. GENENTECH, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 39. GENENTECH, INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 40. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 41. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 42. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 43. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 45. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 46. ONYX PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 47. ONYX PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 48. ONYX PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 49. PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 50. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 51. PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Kidney/Renal Cancer Drugs Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Kidney/renal Cancer Drugs Market

Kidney/Renal Cancer Drugs Market

by Therapy Type (Targeted Therapy, Chemotherapy, Immunotherapy): Global Opportunity Analysis and Industry Forecast, 2023-2032

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: KIDNEY/RENAL CANCER DRUGS MARKET, BY THERAPY TYPE

4.1. Market Overview

4.1.1 Market Size and Forecast, By Therapy Type

4.2. Targeted Therapy

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.2.4. Approved drugs

4.2.4.1. Market Size and Forecast

4.2.4. Pipeline drugs

4.2.4.1. Market Size and Forecast

4.3. Chemotherapy

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

4.4. Immunotherapy

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.4.2. Market Size and Forecast, By Region

4.4.3. Market Share Analysis, By Country

CHAPTER 5: KIDNEY/RENAL CANCER DRUGS MARKET, BY REGION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Region

5.2. North America

5.2.1. Key Market Trends and Opportunities

5.2.2. Market Size and Forecast, By Therapy Type

5.2.3. Market Size and Forecast, By Country

5.2.4. U.S. Kidney/renal Cancer Drugs Market

5.2.4.1. Market Size and Forecast, By Therapy Type

5.2.5. Canada Kidney/renal Cancer Drugs Market

5.2.5.1. Market Size and Forecast, By Therapy Type

5.2.6. Mexico Kidney/renal Cancer Drugs Market

5.2.6.1. Market Size and Forecast, By Therapy Type

5.3. Europe

5.3.1. Key Market Trends and Opportunities

5.3.2. Market Size and Forecast, By Therapy Type

5.3.3. Market Size and Forecast, By Country

5.3.4. France Kidney/renal Cancer Drugs Market

5.3.4.1. Market Size and Forecast, By Therapy Type

5.3.5. Germany Kidney/renal Cancer Drugs Market

5.3.5.1. Market Size and Forecast, By Therapy Type

5.3.6. Italy Kidney/renal Cancer Drugs Market

5.3.6.1. Market Size and Forecast, By Therapy Type

5.3.7. Spain Kidney/renal Cancer Drugs Market

5.3.7.1. Market Size and Forecast, By Therapy Type

5.3.8. UK Kidney/renal Cancer Drugs Market

5.3.8.1. Market Size and Forecast, By Therapy Type

Kidney/Renal Cancer Drugs Market
Global Opportunity Analysis and Industry Forecast, 2023-2032